- Home
- ERH vs RLMD Comparison
ERH vs RLMD Comparison
Compare ERH & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERH
- RLMD
- Stock Information
- Founded
- ERH 2004
- RLMD 2004
- Country
- ERH United States
- RLMD United States
- Employees
- ERH N/A
- RLMD N/A
- Industry
- ERH Finance/Investors Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ERH Finance
- RLMD Health Care
- Exchange
- ERH Nasdaq
- RLMD Nasdaq
- Market Cap
- ERH 97.6M
- RLMD 110.6M
- IPO Year
- ERH N/A
- RLMD N/A
- Fundamental
- Price
- ERH $10.57
- RLMD $0.36
- Analyst Decision
- ERH
- RLMD Hold
- Analyst Count
- ERH 0
- RLMD 3
- Target Price
- ERH N/A
- RLMD $5.33
- AVG Volume (30 Days)
- ERH 23.2K
- RLMD 2.1M
- Earning Date
- ERH 01-01-0001
- RLMD 11-07-2024
- Dividend Yield
- ERH 8.85%
- RLMD N/A
- EPS Growth
- ERH N/A
- RLMD N/A
- EPS
- ERH N/A
- RLMD N/A
- Revenue
- ERH N/A
- RLMD N/A
- Revenue This Year
- ERH N/A
- RLMD N/A
- Revenue Next Year
- ERH N/A
- RLMD N/A
- P/E Ratio
- ERH N/A
- RLMD N/A
- Revenue Growth
- ERH N/A
- RLMD N/A
- 52 Week Low
- ERH $7.97
- RLMD $0.35
- 52 Week High
- ERH $10.91
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- ERH 33.34
- RLMD 16.59
- Support Level
- ERH $10.51
- RLMD $0.35
- Resistance Level
- ERH $10.96
- RLMD $0.41
- Average True Range (ATR)
- ERH 0.09
- RLMD 0.16
- MACD
- ERH -0.06
- RLMD -0.11
- Stochastic Oscillator
- ERH 8.11
- RLMD 0.38
About ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.